NAMS:NASDAQNewAmsterdam Pharma Company N.V. analysis
Data as of Oct 14, 2026 - not real-time
- Latest price
- $20.01
- Risk: high
- 9/10High risk
Summary
NewAmsterdam Pharma Company N.V. is priced at $20.01 and its moving averages line up in bearish order, the shorter trailing the longer. Across the trailing 30 sessions it lost 19.7%. Momentum indicators put RSI at 29.6 (oversold) with MACD reading bearish. Watch $19.58 as support and $25.12 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 147.4% above the current quote. Revenue is contracting at 80.7%.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 54.2%, a beta of 1.28 and a maximum drawdown of 51.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
All three time horizons resolve to sell, carrying 4/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 147.4% above the current quote. Revenue is contracting at 80.7%.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 54.2%, a beta of 1.28 and a maximum drawdown of 51.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
All three time horizons resolve to sell, carrying 4/10 conviction.
Top market events
- NewAmsterdam Pharma Company N.V. NASDAQ:NAMS has cleared a major regulatory hurdle.
- NewAmsterdam Pharma Company N.V. NASDAQ:NAMS has cleared a major regulatory hurdle. On September 21, it announced...
- /PRNewswire/ -- NewAmsterdam Pharma Company N.
Market outlook
Short term
< 1 yearCautious
Model confidence5/105 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- RSI at 29.6 signals oversold conditions
- Trading below the 200-day average of 30.61
Medium term
1–3 yearsCautious
Model confidence4/104 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- RSI at 29.6 signals oversold conditions
- Trading below the 200-day average of 30.61
Long term
> 3 yearsCautious
Model confidence4/104 out of 10
Key factors
- Analyst targets imply +147.4% versus the current price
- Negative return on equity of -36.8%
- Revenue contracting at -80.7%
Key metrics
Financial health
Revenue Growth-80.70%
P/E Ratio-13.2
ROE-36.81%
ROA-20.11%
Debt/Equity0.01
P/B Ratio3.7
Op. Cash Flow$-143462000
Free Cash Flow$-45358376
Industry P/E31.0
Technical analysis
TrendBearish
RSI29.6
Support$19.58
Resistance$25.12
MA 20$22.44
MA 50$24.53
MA 200$30.61
MACDBearish
VolumeDecreasing
Fear & Greed Index91.3
Valuation
Target Price$49.50
Upside/Downside147.35%
GradeFair
TypeBlend
Risk assessment
Beta1.28
Volatility54.20%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar tickers
TCX
Tucows Inc.
stockDLY
DoubleLine Yield Opportunities Fund
closed_end_fundWHF
WhiteHorse Finance, Inc.
stock836
China Resources Power Holdings Co. Ltd.
stockSPME
Sound Point Meridian Capital, Inc. 7.875% Series B Preferred Shares due 2030
stockEDN
Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
stockThis analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.